Figure 1: Co-delivery of melarsoprol and lenalidomide using AEAA-targeted erythrocyte membrane-coated PLGA NP for modulating the cGAS-STING pathway to reverse immunosuppressive TME and achieve chemoimmunotherapy to HCC. (IMAGE)

KeAi Communications Co., Ltd.

Figure 1: Co-delivery of melarsoprol and lenalidomide using AEAA-targeted erythrocyte membrane-coated PLGA NP for modulating the cGAS-STING pathway to reverse immunosuppressive TME and achieve chemoimmunotherapy to HCC.

Caption

Figure 1: Co-delivery of melarsoprol and lenalidomide using AEAA-targeted erythrocyte membrane-coated PLGA NP for modulating the cGAS-STING pathway to reverse immunosuppressive TME and achieve chemoimmunotherapy to HCC.

Credit

Yu Z, Zou Y F, Han S L, et al.

Usage Restrictions

Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.

License

CC BY-NC-ND

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.